Immunotherapy combo shows promise in Early-Stage melanoma
NCT ID NCT05418972
First seen Nov 19, 2025 · Last updated May 25, 2026 · Updated 24 times
Summary
This study tests whether giving two immunotherapy drugs (relatlimab and nivolumab) before surgery can shrink or eliminate tumors in people with high-risk stage II melanoma. About 20 participants will receive two doses of the drugs, then have surgery to remove any remaining cancer. The goal is to see how many patients have a complete or near-complete response, meaning few or no cancer cells left in the removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE II MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Melanoma Institute Australia
Wollstonecraft, New South Wales, 2065, Australia
Conditions
Explore the condition pages connected to this study.